Stephen M. Hinshaw, Linjie Yuan, Md Abdullah Al Noman, Michael Martinez, Gianna M. Colombo, Brendan G. Dwyer, Wenzhi Ji, Bryan A. Romero, Ines Forrest, Joey Lu, Jing Bian, Trae B. Dunn, Ethan Garvin, Daniel Fernandez, Tinghu Zhang, Nathanael S. Gray, Steven M. Corsello
Molecular glues that induce new protein interactions can be potent therapeutics. We and others recently discovered that the small molecule PRLX-93936 (PRLX), which was originally developed as an erastin derivative with antitumor activity, is a molecular glue that alters the substrate specificity of the TRIM21 ubiquitin ligase. PRLX causes TRIM21 to bind the nuclear pore protein NUP98, triggering nuclear pore complex (NPC) degradation. We present here the structural and biochemical basis of NUP98 recognition, finding that ternary complex assembly depends on the creation of a composite TRIM21-small molecule surface competent for NUP98 binding. A scarcity of direct small molecule-NUP98 contacts likely explains how multiple structurally diverse TRIM21 ligands can induce NPC degradation. We also report the discovery of an enhanced molecular glue, MAN-021, and describe its structure. Our findings provide a basis for rational development of next-generation small molecules with enhanced or differentiated activities.